10-Year trends in the diagnosis and treatment of hepatitis C and concomitant mental health disorders: 1995 to 2005

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 10, Issue 5, 2008, Pages 349-354

  Yawn, Barbara P ^a   Rocca, Liliana Gazzuola ^a   Wollan, Peter C ^a  

^a OLMSTED MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOLISM; ARTICLE; BIPOLAR DISORDER; COMORBIDITY; DEPRESSION; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; ENZYME IMMUNOASSAY; HEPATITIS C; HUMAN; IMMUNOBLOTTING; INTRAVENOUS DRUG ABUSE; MAJOR DEPRESSION; MEDICAL RECORD; MENTAL DISEASE; PERSONALITY DISORDER; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; REGISTER; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 54349097728     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/pcc.v10n0501     Document Type: Article

References (40)

1. National Hepatitis C Prevention Strategy. Hepatitis C Infection in the United States. Center for Disease Control. Available at: www.cdc.gov. Accessed Dec 15, 2007
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005 Sep;5(9):558-567
3. Sy T, Jamal M. Epidemiology of hepatitis C virus (HCV) infection. J Med Sci 2006;3(2):41-46
4. Cooke GS, Main J. Improving the treatment of hepatitis C infection in the UK. Expert Opin Pharmcother 2007 Feb;8(2):183-191
5. Consensus conference. Treatment of hepatitis C. Gastroenterol Clin Biol 2002;26 Spec No 2:B303-B320
6. Souvignet C, Lejeune O, Trepo C. Interferon-based treatment of chronic hepatitis C. Biochimie 2007 Jun-Jul;89(6-7):894-898
7. Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007 Mar;11(11):1-205
8. Weigand K, Stremmel W, Encke J. Treatment of hepatitis C virus infection. World J Gastroenterol 2007;13(13):1897-1905
9. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355(23):2444-2451
10. Rocca LG, Yawn BP, Wollan P, et al. Management of patients with hepatitis C in a community population: diagnosis, discussions, and decisions to treat. Ann Fam Med 2004;2(2):116-124
11. Morrill J, Shrestha M. Barriers to the Treatment of Hepatitis C: patient, provider and system factors. J Gen Intern Med 2005;20(8):754-758
12. Butt AA, Khan UA, McGinnis KA, et al. Co-morbid medical and psychiatric illness and substance abuse in HCV-infected and uninfected veterans. J Vital Hepat 2007 Dec;14(12):890-896
13. Rowan PJ, Dunn NJ, El-Serag HB, et al. Views of hepatitis C virus patients delayed from treatment for psychiatric reasons. J Viral Hepat 2007;14(12):883-889
14. Flack-Ytter Y, Kale H, Mullen K, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136(4):288-292
15. Crone C, Gabriel GM. Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. J Psychiatr Pract 2003;9(2):93-110
16. Schaefer M, Schwaiger M, Garkisch A, et al. Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. J Hepatol 2005;42(6):793-798
17. Fireman M, Indest DW, Blackwell A, et al. Addressing tri-morbidity (hepatitis C, psychiatric disorders, and substance use): the importance of routine mental health screening as a component of a comanagement model of care. Clin Infect Dis 2005 Apr;40(suppl 5):S286-S291
18. Reimer J, Schulte B, Castells X, et al. Guidelines for the treatment of hepatitis C virus infection in injection drug users: status quo in the European Union countries. Clin Infect Dis 2005 Apr;40(suppl 5):S373-S378
19. Novick DM. The impact of hepatitis C virus infection on methadone maintenance treatment. Mt Sinai J Med 2000 Oct-Nov;67(5-6):437-443
20. Birkhead GS, Klein SJ, Candelas AR, et al. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach. Int J Drug Policy 2007;18(5):417-425
21. Nunes D, Saitz R, Libman H, et al. Barriers to treatment of hepatitis C in HIV/HCV-coinfected adults with alcohol problems. Alcohol Clin Exp Res 2006;30(9):1520-1526
22. Mathurin P, Canva V, Dharancy S, et al. Treatment of chronic hepatitis C and alcohol consumption. Gastroenterol Clin Biol 2002 Apr;26 Spec No 2:B248-B251
23. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol 2007 Jun;21(suppl C):25C-34C
24. Yawn BP, Gazzuola L, Wollan PC, et al. Development and maintenance of a community-based hepatitis C registry. Am J Manag Care 2002 Mar;8(3):253-261
25. Melton LJ. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71(3):266-274
26. Kurland LT, Molgaard CA. The patient record in epidemiology. Sci Am 1981;245(4):54-63
27. Yawn BP, Yawn RA, Geier GR, et al. The impact of requiring patient authorization for use of data in medical records research. J Fam Pract 1998;47(5):361-365
28. Jacobsen SJ, Xia Z, Campion ME, et al. Potential effect of authorization bias on medical records research. Mayo Clin Proc 1999;74(4):330-338
29. Yawn BP, Wollan P, Gazzuola L, et al. Diagnosis and 10-year follow-up of a community-based hepatitis C cohort. J Fam Pract 2002;51(2):135-140
30. Vignau J, Karila L, Costisella O, et al. Hepatitis C, interferon a and depression: main physiopathologic hypothesis. Encephale 2005;31(3):349-357
31. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003;37(2):443-451
32. Maddock C, Baita A, Orrù MG, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004;18(1):41-46
33. Clark EC, Yawn BP, Galliher JM, et al. Hepatitis C identification and management by family physicians. Fam Med 2005;37(9):644-649
34. Lang JP, Meyer N, Doffoel M. [Benefits of a preventive psychiatric accompaniment in patients hepatitis C virus seropositive (HCV): prospective study concerning 39 patients]. Encephale 2003;29(4, pt 1):362-365
35. Cullen W, Stanley J, Langton D, et al. Hepatitis C infection among injecting drug users in general practice: a cluster randomized controlled trial of clinical guidelines' implementation. Br J Gen Pract 2006;56(532):848-856
36. Farrell GC. New hepatitis C guidelines for the Asia-Pacific region: APASL consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22(5):607-610
37. Pol S, Mallet VO. Improving anti-hepatitis C virus therapy. Expert Opin Biol Ther 2006;6(9):923-933
38. Watson B, Conigrave KM, Wallace C, et al. Hazardous alcohol consumption and other barriers to antiviral treatment among hepatitis C positive people receiving opioid maintenance treatment. Drug Alcohol Rev 2007;26(3):231-239
39. Beaulieu PL. Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections. Curr Opin Investig Drugs 2007;8(8):614-634
40. Asselah T, Bieche I, Paradis V, et al. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 2007;27(1):13-27